Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Inclusion Criteria: * Histological evidence of non-CNS malignancy (primary or metastatic disease) and lymphomas which are not involving the bone marrow. * Undergoing single or multiple days of chemotherapy as long as Day 1 chemotherapy includes: 1. a moderate-to-high emetogenic regimen, or 2. oxaliplatin at doses employed for treatment of colon cancer, or 3. the combination of AC \[AdriamycinÒ (60 mg/m2) with cyclophosphamide (600 mg/m2)\] as to be used for the chemotherapeutic drug regimen involving taxanes in the treatment of breast cancer. Exclusion Criteria: * Chemotherapy agents falling into the low (Level 1), moderate-to-low (Level 2), moderate (Level 3) unless used in combination with a Level 4 chemotherapy agent on Day 1 of the study. * Chemotherapy agents falling into the high (Level 5) classification during study. * Any combination of chemotherapy agents that does not fall into the moderate-to-high (Level 4) classification